BACKGROUND The BRAF inhibitor vemurafenib is state of the art in therapy of patients with malignant melanoma in non-resectable stage III or stage IV and evidence of oncogenetic BRAF mutation. Multiple cutaneous side effects like rash and keratoacanthoma-like lesions have been described so far. CASE REPORT We report a patient who presented multiple wart-like lesions under therapy with vemurafe...

formed.Theexanthemaandtheeosinophiliadecreasedgradually until normalization was achieved on day 16. On day 19, vemurafenib therapy was discontinued, and within 7days thereafter, the feverhad improved, and theelectrolyte profile had normalized. Tumor assessment showed a major tumoral response. On day 29, vemurafenib treatment was restarted at half dose, leading within 21 days (day 50) to a relap...

BRAF inhibitors are broadly used for metastatic melanoma with BRAF mutations. Their use results in various cutaneous side effects, such as the development of keratoacanthomas and squamous cell carcinomas. We report a patient with metastatic melanoma treated with vemurafenib who developed dozens of histologically confirmed epidermal cysts within 2 months after initiation of vemurafenib administr...

Background Mutations in BRAF V600E oncogene (BRAFMT) occurs in 8-15% of colorectal cancer (CRC) patients1. This mutation constitutively activates MAPK signalling, resulting in a proliferative and survival advantage for the tumour cells and oncogenic BRAF status has been linked with poor prognosis2. Despite introduction of the BRAFMT specific inhibitor Vemurafenib in metastatic melanoma3, there ...

Despite recent advancements in the treatment of late-stage mutant BRAF (V600E/K) melanomas, a major hurdle continues to be acquired resistance to BRAF inhibitors such as vemurafenib. The mechanisms for resistance have proven to be heterogeneous, emphasizing the need to use broad therapeutic approaches. In this issue, the study "Stat3-targeted therapies overcome the acquired resistance to vemura...

Abstract PURPOSE Standard of care for craniopharyngiomas is surgery with or without radiotherapy (RT). Cohort A Alliance A071601 evaluated the efficacy BRAF/MEK inhibition vemurafenib/cobimetinib in patients previously untreated papillary (PCP), which carry BRAF V600E mutation. B currently enrolling recurrence after RT. In a correlative analysis, we examined changes RT volumes therapy A. METHOD...

Combination therapies for the treatment of metastatic melanoma are a matter of debate nowadays. We report on a stage IV metastatic melanoma patient with the BRAF V600 mutation and a large tumor burden initially treated with two cycles of ipilimumab. Due to dramatic disease progression, demonstrated on interim 18F-FDG PET/CT, vemurafenib was added in the patient's therapeutical scheme. After com...